Amneal (AMRX): Beat, Raised Guidance Twice — And Fell 5%. First-Half Cash Flow Was NEGATIVE $48M

Amneal Pharmaceuticals (AMRX) Q2 2026 — Amneal Pharmaceuticals (AMRX) — the Patel brothers' complex-generics and branded-neurology drugmaker — reported Q2 2026 (quarter ended June 30) before the open on July 30. Net revenue was $796.2M (+10%), adjusted EPS $0.30 (+20%), adjusted EBITDA $206.5M (+12%), and management RAISED full-year guidance for the second time this year. The stock still fell about 5% to $18.21 after closing at a record $19.10. Why: first-half operating cash flow was NEGATIVE $47.99M versus POSITIVE $91.2M a year ago, net debt rose $244M to $2.66B, and net leverage ticked UP to 3.6x. Our free-cash-flow-to-equity DCF lands at ~$15 vs $18.21. Our call: HOLD, 3/5. This was a good quarter by almost every reported measure — and the market sold it anyway. Amneal grew revenue 10% to $796.2M, expanded gross margin from 39.5% to 42.0%, grew adjusted EBITDA 12% to $206.5M, and raised FY2026 guidance to $3.10-3.20B revenue, $750-780M adjusted EBITDA and $0.96-1.06 adjusted EPS. Specialty revenue rose 17% to $149.3M on CREXONT, BREKIYA and UNITHROID at an 80.3% adjusted gross margin; Affordable Medicines rose 13% to $489.9M. But three things sit underneath the headline. First, the celebrated 157% GAAP earnings jump to $0.18 is largely a tax artifact: the provision was $1.376M, an effective rate under 2%, against 31% a year ago — pre-tax income rose 37% while net income rose 96%. Second, the cash. Six-month operating cash flow was negative $47.99M against positive $91.2M last year as receivables built $125.8M and inventories built $124.2M; cash fell from $282.0M to $127.6M, net debt rose to $2.657B and net leverage rose to 3.6x from 3.5x even as EBITDA grew. The full-year guide of $350-400M operating cash flow now requires roughly $400-450M in the back half. Third, the raise was small — revenue up $50M at the midpoint (1.6%), adjusted EBITDA up $10M, adjusted EPS up a single penny — after a quarter that beat by 10% on revenue. Credit where due: the July repricing of the $2.084B Term Loan B from SOFR+300 to SOFR+250 saves ~$12M a year, and interest expense already fell from $65.1M to $55.0M. But another $350M term loan is coming to fund the Kashiv BioSciences acquisition, and the sub-3.0x leverage target is not until 2028. Bridging guided adjusted EBITDA of ~$765M down through cash interest, capex, cash taxes, minority distributions and working capital leaves roughly $240M of free cash flow to equity — a ~4% yield. Our DCF lands at $10.90 (guidance path, 10%) to $16.50 (Specialty + biosimilars path, 9%); ~10x FY26 EBITDA less net debt gives ~$15. We call fair value $15.00 versus the $18.21 price — about 18% below. THE CALL: HOLD (3/5, A REAL TURNAROUND THAT HAS ALREADY RE-RATED 133% — AND THE CASH STILL HASN'T SHOWN UP) — base-case value ~$15.00 vs ~$18.21 today. What to watch: second-half operating cash flow actually landing inside the $350-400M guide, net leverage printing below 3.5x and falling, and Specialty crossing 20% of total revenue. The risks: working capital that never unwinds so the cash-flow guide gets cut, the Kashiv acquisition pushing gross debt past $3.1B without the EBITDA to match, or a generic price-deflation quarter — at 3.6x levered, a stumble hits the equity far harder than the business Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.